

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10575977	
	Filing Date		2007-05-02	
	First Named Inventor	Haijun Sun		
	Art Unit	1647		
	Examiner Name	DEBERRY, Regina M		
Attorney Docket Number		X-18530		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2005/037235	WO		2005-04-28	Imclone Systems, Inc.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575977
Filing Date	2007-05-02
First Named Inventor	Haijun Sun
Art Unit	1647
Examiner Name	DEBERRY, Regina M
Attorney Docket Number	X-18530

1	ABATH and SIMPSON, "A Simple Method for the Recovery of Purified Recombinant Peptides Cleaved from Glutathione-S-Transferase-Fusion Proteins," Peptide Research, 3(4):167-168 (1990)	<input type="checkbox"/>
2	AUSUBEL et al., "Short Protocols in Molecular Biology", Current Protocols in Molecular Biology, 1:2.20.3, Green Publishing Associates, Inc., and John Wiley & Sons, Inc, New York (1989)	<input type="checkbox"/>
3	BAYES et al., "Gateways To Clinical Trials," Methods and Findings in Experimental and Clinical Pharmacology, 25 (6):483-506 at 491, Prous, Barcelona, Spain (July 2003)	<input type="checkbox"/>
4	BLANCKAERT et al., "Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1," Hybridoma and Hybridomics, 21(3): 153-159 (June 2002)	<input type="checkbox"/>
5	BOERNER et al., "Production of Antigen-Specific Human Monoclonal Antibodies from in vitro-primed human splenocytes1," J. Immunol, 147(1):86-95 (1991)	<input type="checkbox"/>
6	DIECKMANN and TZAGOLOFF, "Assembly of the Mitochondrial Membrane System," J. Biol. Chem., 260:1513-1520 (1985)	<input type="checkbox"/>
7	FISHWILD et al., "High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice," Nature Biotechnology, 14:845-51 (1996)	<input type="checkbox"/>
8	SMITH, et al., "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene, 67:31-40 (1988)	<input type="checkbox"/>
9	HOOGENBOOM and WINTER, "By-passing Immunisation Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro," J. Mol Biol., 227:381 (1991)	<input type="checkbox"/>
10	JOHNSON et al., "The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain," Molecular and Cellular Biology, 11(9): 4627-4634 (September 1991)	<input type="checkbox"/>
11	KAUFMANN and SHARP, "Amplification and Expression of Sequences Cotransfected with A Modular Dihydrofolate Reductase Complementary DNA Gene," J. Mol. Biol., 159:601-621 (1982)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575977
Filing Date	2007-05-02
First Named Inventor	Haijun Sun
Art Unit	1647
Examiner Name	DEBERRY, Regina M
Attorney Docket Number	X-18530

12	KOSTRZEWA et al., "Genomic structure and complete sequence of the human FGFR4 gene," Mammalian Genome: Official Journal of the International Mammalian Genome Society, 9(2):131-135 (February 1998)	<input type="checkbox"/>
13	LONBERG and HUSZAR, "Human Antibodies from Transgenic Mice," Intern Rev. Immunol, 13:65-93 (1995)	<input type="checkbox"/>
14	LONBERG et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications", Nature, 368:856-859 (1994)	<input type="checkbox"/>
15	MARKS et al., "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage," J. Mol. Biol., 222:581 (1991)	<input type="checkbox"/>
16	MORRISON, "Success in specification," Nature, 368:812-813 (1994)	<input type="checkbox"/>
17	NEUBERGER, " Generating high-avidity human Mabs in mice," Nature Biotechnology, 14:826 (1996)	<input type="checkbox"/>
18	PARTRIDGE et al., "Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration," Journal of Cellular Biochemistry, 78(3):487-499 (June 6, 2000)	<input type="checkbox"/>
19	POWERS et al., "Fibroblast growth factors, their receptors and signaling," Endocrine Related Cancer, 7:165-197 at 165-197 (2000)	<input type="checkbox"/>
20	SKAPER et al., "The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects," Journal of Neurochemistry, 75(4):1520-1527 (October 2000)	<input type="checkbox"/>
21	SOUTHERN and BERG, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," J. Mol. Appl. Genet., 1:327-341 (1982)	<input type="checkbox"/>
22	STEGE et al., "Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium." Histochemistry and Cell Biology, 110(1):57-62, Germany (1998)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10575977
Filing Date	2007-05-02
First Named Inventor	Haijun Sun
Art Unit	1647
Examiner Name	DEBERRY, Regina M
Attorney Docket Number	X-18530

23	SUN et al., "Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys." American Journal of Physiology, Endocrinology and Metabolism, 292(3):E964-E976 (March 2007)	<input type="checkbox"/>
24		<input type="checkbox"/>
25		<input type="checkbox"/>
26		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.